晚期黏液性上皮性卵巢癌的国际III期随机试验(mEOC/GOG 0241)长期随访:在罕见妇科肿瘤中开展临床试验的经验
多中心随机析因试验纳入50例晚期黏液性上皮性卵巢癌患者,比较紫杉醇-卡铂与奥沙利铂-卡培他滨(各联合或不联合贝伐珠单抗)的疗效。因入组缓慢提前终止,中位随访59个月,总生存风险比在两组主要比较中分别为0.78(P=0.48)和1.04(P=0.92),均未达统计学显著。回顾性中心病理复核仅45%(18/40)病例确诊原发性黏液性上皮性卵巢癌。
要点
- 试验因入组缓慢在50例患者后提前终止,主要疗效比较均未达统计学显著。
- 奥沙利铂-卡培他滨 vs 紫杉醇-卡铂的总生存HR为0.78(P=0.48)。
- 贝伐珠单抗 vs 无贝伐珠单抗的总生存HR为1.04(P=0.92)。
核心结论
- mEOC/GOG0241是罕见肿瘤随机试验的一个实例,因后勤挑战而提前终止,包括局部组织病理诊断困难和超说明书用药获取困难。
- 支持罕见癌症临床试验的中心资助方与地方层面研究管理和资助方对此类工作的降级之间存在错位。
- 罕见癌症试验应在治疗前纳入中心化病理复核。
研究设计与样本
- 多中心随机析因试验(英国和美国),纳入原发性黏液性上皮性卵巢癌患者,FIGO分期II-IV期或I期疾病后复发。
- 治疗臂为紫杉醇-卡铂、奥沙利铂-卡培他滨、紫杉醇-卡铂-贝伐珠单抗或奥沙利铂-卡培他滨-贝伐珠单抗。
- 化疗每3周一次共6个周期,贝伐珠单抗(每3周一次)继续作为维持治疗共12个周期。
- 终点包括总生存、无进展生存、毒性和生活质量。
- 试验在入组50例患者后因入组缓慢而停止,中位随访59个月。
主要发现
- 两个主要比较的总生存风险比:奥沙利铂-卡培他滨 vs 紫杉醇-卡铂(各联合或不联合贝伐珠单抗)为0.78(P=0.48);贝伐珠单抗 vs 无贝伐珠单抗为1.04(P=0.92)。
- 相应的无进展生存风险比分别为0.84和0.80。
- 回顾性中心病理复核显示,仅有45%(18/40)有可用材料的病例确诊为原发性黏液性上皮性卵巢癌。
- 在确诊患者中,奥沙利铂-卡培他滨 vs 紫杉醇-卡铂的总生存风险比为0.36(P=0.14),无进展生存风险比为0.62(P=0.40)。
- 3-4级毒性发生率:紫杉醇-卡铂组61%,奥沙利铂-卡培他滨组61%,紫杉醇-卡铂-贝伐珠单抗组54%,奥沙利铂-卡培他滨-贝伐珠单抗组85%;四组生活质量相似。
临床怎么用
- 作者认为罕见癌症试验应在治疗前纳入中心化病理复核。
局限性
- 试验因入组缓慢在50例患者后提前终止。
- 回顾性中心病理复核显示仅有45%(18/40)有可用材料的病例确诊为原发性黏液性上皮性卵巢癌。
- 存在局部组织病理诊断困难和超说明书用药获取困难等后勤挑战。
- 支持罕见癌症临床试验的中心资助方与地方层面研究管理和资助方对此类工作的降级之间存在错位。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We evaluated four different treatment regimens for advanced-stage mucinous epithelial ovarian cancer. METHODS: We conducted a multicenter randomized factorial trial (UK and US). Patients were diagnosed with primary mEOC: FIGO stage II-IV or recurrence after stage I disease. Treatment arms were paclitaxel-carboplatin, oxaliplatin-capecitabine, paclitaxel-carboplatin-bevacizumab, or oxaliplatin-capecitabine-bevacizumab. Chemotherapy was given 3-weekly for 6 cycles, and bevacizumab (3-weekly) was continued as maintenance (for 12 cycles). Endpoints included overall-survival (OS), progression-free survival (PFS), toxicity and quality of life (QoL). RESULTS: The trial stopped after 50 patients were recruited due to slow accrual. Median follow-up was 59 months. OS hazard ratios (HR) for the two main comparisons were: 0.78 (p = 0.48) for Oxal-Cape vs. Pac-Carbo (each with/without bevacizumab), and 1.04 (p = 0.92) for bevacizumab vs. no bevacizumab. Corresponding PFS HRs were: 0.84 and 0.80. Retrospective central pathology review revealed only 45% (18/40) cases with available material had confirmed primary mEOC. Among these, OS HR for Oxal-Cape vs. Pac-Carbo was 0.36 (p = 0.14); PFS HR = 0.62 (p = 0.40). Grade 3-4 toxicity was seen in 61% Pac-Carbo, 61% Oxal-Cape, 54% Pac-Carbo-Bev, and 85% Oxal-Cape-Bev. QoL was similar between the four arms. CONCLUSION: mEOC/GOG0241 represents an example of a randomized rare tumor trial. Logistical challenges led to early termination, including difficulties in local histopathological diagnosis and accessing drugs outside their labelled indication. There was misalignment between central funders who support clinical trials in rare cancers and the deprioritisation of such work by those managing and funding research at a local level. Rare cancer trials should include centralised pathology review before treatment. Clinical trial registry number: ISRCTN83438782.
引用
- Gore M, Hackshaw A, Brady WE, et al. An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor. Gynecol Oncol. 2019. PMID: 31005287. doi:10.1016/j.ygyno.2019.03.256
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。